tiprankstipranks
Trending News
More News >
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
US Market

Belite Bio, Inc. ADR (BLTE) Stock Forecast & Price Target

Compare
59 Followers
See the Price Targets and Ratings of:

BLTE Analyst Ratings

Strong Buy
7Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Belite
Bio, Inc. ADR
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BLTE Stock 12 Month Forecast

Average Price Target

$215.29
▲(23.73% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Belite Bio, Inc. ADR in the last 3 months. The average price target is $215.29 with a high forecast of $266.00 and a low forecast of $200.00. The average price target represents a 23.73% change from the last price of $174.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","267":"$267","108.75":"$108.8","161.5":"$161.5","214.25":"$214.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":266,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$266.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":215.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$215.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$200.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,108.75,161.5,214.25,267],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.58,184.38153846153847,191.18307692307692,197.98461538461538,204.78615384615387,211.58769230769232,218.38923076923078,225.19076923076923,231.9923076923077,238.79384615384618,245.5953846153846,252.3969230769231,259.1984615384615,{"y":266,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.58,180.48076923076925,183.38153846153847,186.2823076923077,189.18307692307692,192.08384615384617,194.98461538461538,197.88538461538462,200.78615384615384,203.68692307692308,206.5876923076923,209.48846153846154,212.38923076923078,{"y":215.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,177.58,179.3046153846154,181.0292307692308,182.75384615384615,184.47846153846154,186.20307692307694,187.92769230769233,189.6523076923077,191.37692307692308,193.10153846153847,194.82615384615386,196.55076923076922,198.2753846153846,{"y":200,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.31,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.58,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$266.00Average Price Target$215.29Lowest Price Target$200.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group
$200
Buy
14.94%
Upside
Reiterated
03/05/26
Belite Bio, Inc. ADR (BLTE) Receives a Buy from Maxim Group
Mizuho Securities Analyst forecast on BLTE
Mizuho Securities
Mizuho Securities
$223
Buy
28.16%
Upside
Reiterated
03/04/26
Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)
H.C. Wainwright Analyst forecast on BLTE
H.C. Wainwright
H.C. Wainwright
$185$200
Buy
14.94%
Upside
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE) and Ocugen (NASDAQ: OCGN)
Morgan Stanley Analyst forecast on BLTE
Morgan Stanley
Morgan Stanley
$191$201
Buy
15.52%
Upside
Reiterated
03/03/26
Morgan Stanley Sticks to Its Buy Rating for Belite Bio, Inc. ADR (BLTE)
Bank of America Securities Analyst forecast on BLTE
Bank of America Securities
Bank of America Securities
$195$200
Buy
14.94%
Upside
Reiterated
03/03/26
Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
Benchmark Co. Analyst forecast on BLTE
Benchmark Co.
Benchmark Co.
$187$217
Buy
24.71%
Upside
Reiterated
03/03/26
Belite Bio price target raised to $217 from $187 at BenchmarkBelite Bio price target raised to $217 from $187 at Benchmark
Cantor Fitzgerald Analyst forecast on BLTE
Cantor Fitzgerald
Cantor Fitzgerald
$200$266
Buy
52.87%
Upside
Reiterated
03/02/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Leerink Partners Analyst forecast on BLTE
Leerink Partners
Leerink Partners
$50$85
Buy
-51.15%
Downside
Reiterated
10/15/25
Leerink Partners Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Maxim Group
$200
Buy
14.94%
Upside
Reiterated
03/05/26
Belite Bio, Inc. ADR (BLTE) Receives a Buy from Maxim Group
Mizuho Securities Analyst forecast on BLTE
Mizuho Securities
Mizuho Securities
$223
Buy
28.16%
Upside
Reiterated
03/04/26
Mizuho Securities Sticks to Their Buy Rating for Belite Bio, Inc. ADR (BLTE)
H.C. Wainwright Analyst forecast on BLTE
H.C. Wainwright
H.C. Wainwright
$185$200
Buy
14.94%
Upside
Reiterated
03/04/26
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (NASDAQ: BLTE) and Ocugen (NASDAQ: OCGN)
Morgan Stanley Analyst forecast on BLTE
Morgan Stanley
Morgan Stanley
$191$201
Buy
15.52%
Upside
Reiterated
03/03/26
Morgan Stanley Sticks to Its Buy Rating for Belite Bio, Inc. ADR (BLTE)
Bank of America Securities Analyst forecast on BLTE
Bank of America Securities
Bank of America Securities
$195$200
Buy
14.94%
Upside
Reiterated
03/03/26
Tinlarebant De‑Risking Milestones and Rare-Disease Upside Support Buy Rating and $200 Price Target
Benchmark Co. Analyst forecast on BLTE
Benchmark Co.
Benchmark Co.
$187$217
Buy
24.71%
Upside
Reiterated
03/03/26
Belite Bio price target raised to $217 from $187 at BenchmarkBelite Bio price target raised to $217 from $187 at Benchmark
Cantor Fitzgerald Analyst forecast on BLTE
Cantor Fitzgerald
Cantor Fitzgerald
$200$266
Buy
52.87%
Upside
Reiterated
03/02/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Leerink Partners Analyst forecast on BLTE
Leerink Partners
Leerink Partners
$50$85
Buy
-51.15%
Downside
Reiterated
10/15/25
Leerink Partners Reaffirms Their Buy Rating on Belite Bio, Inc. ADR (BLTE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Belite Bio, Inc. ADR

3 Months
xxx
Success Rate
10/12 ratings generated profit
83%
Average Return
+29.78%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +29.78% per trade.
1 Year
Marc GoodmanLeerink Partners
Success Rate
12/12 ratings generated profit
100%
Average Return
+121.68%
reiterated a buy rating 5 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +121.68% per trade.
2 Years
xxx
Success Rate
12/12 ratings generated profit
100%
Average Return
+199.38%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +199.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BLTE Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
1
0
0
0
0
Buy
8
10
12
10
13
Hold
2
3
8
12
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
13
20
22
24
In the current month, BLTE has received 13 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. BLTE average Analyst price target in the past 3 months is 215.29.
Each month's total comprises the sum of three months' worth of ratings.

BLTE Financial Forecast

BLTE Earnings Forecast

Next quarter’s earnings estimate for BLTE is -$0.64 with a range of -$0.96 to -$0.47. The previous quarter’s EPS was -$0.38. BLTE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BLTE has Performed in-line its overall industry.
Next quarter’s earnings estimate for BLTE is -$0.64 with a range of -$0.96 to -$0.47. The previous quarter’s EPS was -$0.38. BLTE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year BLTE has Performed in-line its overall industry.
No data currently available

BLTE Sales Forecast

Next quarter’s sales forecast for BLTE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BLTE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BLTE has Performed in-line its overall industry.
Next quarter’s sales forecast for BLTE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. BLTE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year BLTE has Performed in-line its overall industry.

BLTE Stock Forecast FAQ

What is BLTE’s average 12-month price target, according to analysts?
Based on analyst ratings, Belite Bio, Inc. ADR’s 12-month average price target is 215.29.
    What is BLTE’s upside potential, based on the analysts’ average price target?
    Belite Bio, Inc. ADR has 23.73% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BLTE a Buy, Sell or Hold?
          Belite Bio, Inc. ADR has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Belite Bio, Inc. ADR’s price target?
            The average price target for Belite Bio, Inc. ADR is 215.29. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $266.00 ,the lowest forecast is $200.00. The average price target represents 23.73% Increase from the current price of $174.
              What do analysts say about Belite Bio, Inc. ADR?
              Belite Bio, Inc. ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of BLTE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.